ABN AMRO Bank N.V. Makes New $7.27 Million Investment in Danaher Corporation $DHR

ABN AMRO Bank N.V. bought a new stake in Danaher Corporation (NYSE:DHR) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 37,877 shares of the conglomerate’s stock, valued at approximately $7,266,000.

Several other institutional investors have also modified their holdings of DHR. WFA of San Diego LLC purchased a new stake in Danaher during the second quarter worth $26,000. Howard Hughes Medical Institute acquired a new position in shares of Danaher during the 2nd quarter worth $27,000. TruNorth Capital Management LLC purchased a new stake in shares of Danaher in the 3rd quarter worth about $28,000. Tripletail Wealth Management LLC acquired a new stake in Danaher in the 3rd quarter valued at about $31,000. Finally, Heartwood Wealth Advisors LLC purchased a new position in Danaher during the 3rd quarter valued at about $37,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

DHR stock opened at $219.31 on Thursday. The stock has a market capitalization of $154.91 billion, a price-to-earnings ratio of 43.51, a price-to-earnings-growth ratio of 2.93 and a beta of 0.91. The company has a quick ratio of 1.51, a current ratio of 1.87 and a debt-to-equity ratio of 0.35. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $242.80. The stock’s fifty day simple moving average is $230.07 and its 200-day simple moving average is $214.68.

Danaher (NYSE:DHR) last released its earnings results on Wednesday, January 28th. The conglomerate reported $2.23 EPS for the quarter, beating the consensus estimate of $2.14 by $0.09. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The firm had revenue of $6.84 billion during the quarter, compared to analyst estimates of $6.79 billion. During the same period in the prior year, the firm posted $2.14 earnings per share. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. Equities research analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 30th. Investors of record on Friday, December 26th were given a $0.32 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s dividend payout ratio (DPR) is currently 25.40%.

Insider Activity at Danaher

In other news, SVP Georgeann Couchara sold 5,174 shares of the company’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the sale, the senior vice president directly owned 2,625 shares in the company, valued at $552,352.50. This represents a 66.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Teri List sold 3,298 shares of Danaher stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the transaction, the director owned 20,762 shares in the company, valued at $4,702,593. The trade was a 13.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 30,248 shares of company stock worth $6,609,663. 11.10% of the stock is owned by company insiders.

Analyst Ratings Changes

DHR has been the topic of several recent research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Danaher in a report on Monday, December 29th. KeyCorp reaffirmed an “overweight” rating on shares of Danaher in a research note on Thursday, January 29th. Morgan Stanley initiated coverage on Danaher in a research report on Monday, December 1st. They set an “overweight” rating and a $270.00 price target for the company. Rothschild & Co Redburn restated a “neutral” rating and issued a $220.00 price objective (down from $245.00) on shares of Danaher in a research report on Wednesday, October 8th. Finally, HSBC increased their price objective on Danaher from $255.00 to $270.00 and gave the company a “buy” rating in a research note on Monday, December 1st. Twenty equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $252.32.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.